OVID News and Press, Ovid Therapeutics Inc. From 06/28/23

Dr. Zhong Zhong joins Ovid as Chief Scientific Officer (CSO) and Dr. Manoj Malhotra assumes role as Chief Medical Officer (CMO) following the planned retirement of Dr. Claude Nicaise Meg Alexander promoted to Chief Strategy Officer Ovid streamlined G&A infrastructure to improve oper...

2023-06-26 08:31:53 ET Ovid Therapeutics ( NASDAQ: OVID ) has announced that the Co. was added to the Russell 3000 Index, effective after the U.S. market opens on June 26, 2023. “Increased exposure through this Index enables prospective investors to take part in the...

NEW YORK, June 26, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives of people affected by brain disorders, today announced that the company was added to the Russell 30...

Initiated collaboration with Graviton Bioscience to develop selective ROCK2 inhibitors for rare neurological diseases Long-term data supporting soticlestat safety, tolerability and seizure-reduction efficacy presented by Takeda at the American Academy of Neurology meeting OV329 Ph...

2023-05-01 07:23:02 ET Ovid Therapeutics ( NASDAQ: OVID ) signed a collaboration agreement with Graviton Bioscience to develop therapies for rare neurological diseases. Ovid said the agreement supports its strategy of building a pipeline of first-in-class mechanisms for sei...

Collaboration to unlock the therapeutic potential of ROCK2 inhibition for rare neurological diseases Couples Ovid capabilities in rare CNS development with Graviton’s expertise in RhoA/ROCK2 signaling pathway to accelerate a series of clinical development programs Development...

Interim 2-year findings show soticlestat appeared generally safe and well tolerated, consistent with prior studies Sustained reduction in frequency of drop seizures among Lennox-Gastaut patients and convulsive seizures among Dravet patients were documented for up to two years Sustained re...

2023-04-24 17:17:27 ET Gainers: Medpace Holdings ( MEDP ) +27% . Jupiter Wellness Acquisition  ( JWAC ) +4% . Rhythm Pharmaceuticals ( RYTM ) +3% . IDEAYA Biosciences ( IDYA ) +3% . Morphic Holding ( MORF ) +3% . Loser...

NEW YORK, April 10, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a  biopharmaceutical company committed to developing medicines that transform the lives of people with epilepsies and seizure-related disorders, today announced that management will present at the 22 nd A...

2023-03-13 08:20:27 ET Ovid Therapeutics press release ( NASDAQ: OVID ): Q4 GAAP EPS of -$0.16 beats by $0.02 . Cash, cash equivalents and marketable securities as of December 31, 2022 totaled $129.0 million. For further details see: Ovid Therapeutics GA...